BioWorld

July 31, 2007

Vivus Gains Evamist Approval, $140M Payment From Partner

Vivus Inc. won FDA approval of its Evamist product, triggering a $140 million milestone payment from a partnership entered earlier this year. (BioWorld Today) Read More

Plasma-Based Drug Firm Talecris Seeking $1B IPO

ImClone, BMS Pump Cash Into Erbitux For Broad Label

Alnylam, Medtronic Expand Deal With RNAi Drug-Device Combos

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for July 14, 2026.

AI-generated illustration of a neuron with tau protein aggregation

AAIC 2026: Age of amyloid is being joined by time of tau

BioWorld

The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...

Modius Spero wearable neuromodulation device

Neurovalens granted FDA approval for PTSD therapy for US veterans

BioWorld

Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 14, 2026

Combination locked out in ATTR-CM? ‘Dead,’ expert says

BioWorld

The synergy – or lack of it – between knockdown drugs and stabilizers in treating transthyretin (TTR)-mediated amyloid cardiomyopathy (ATTR-CM) became one of the...